Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts is a research paper published in Translational Oncology (2021). On theSindex it has a DataRank of 0.494. It has been cited 26 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.494
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Canadian Institutes of Health Research
Grant: FDN-148395
Canadian Institutes of Health Research
Grant: PJT-175190
FWCI
1.26
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals